Gilead Sciences | GILD - PE Price to Earnings


Gilead Sciences reported 13.51 in PE Price to Earnings for its fiscal quarter ending in June of 2026.





Pe Change Date
AbbVie 23.96 0.93 Jun/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
ALKERMES 135.81 96.48 Jun/2026
Alnylam Pharmaceuticals 75.64 4.4 Jun/2026
Amgen 18.07 1.77 Jun/2026
Biogen 23.23 9.53 Jun/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Bristol-Myers Squibb 16.14 7.06 Jun/2026
Eli Lilly 32.9 7.37 Jun/2026
Gilead Sciences 13.51 4.2 Jun/2026
GlaxoSmithKline 10.63 4.24 Jun/2026
Glaxosmithkline 15.09 3.43 Mar/2026
Incyte 14.45 0.9 Jun/2026
J&J 29.43 4.9 Jun/2026
Merck 32.26 15.74 Jun/2026
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 22.1 5.99 Jun/2026
Novartis 22.41 2.24 Jun/2026
Pfizer 11.48 2.16 Jun/2026
PTC Therapeutics 8.76 1.22 Mar/2026
Puma Biotechnology 13.93 44.88 Jun/2024
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Sanofi 18.96 7.12 Jun/2026
Sarepta Therapeutics 27.27 0 Mar/2026
United Therapeutics 19.15 1.27 Jun/2026
Vertex Pharmaceuticals 28.05 2.22 Jun/2026